Clinical trial
Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain…
NCT00362583 · Nycomed, Industry · Completed
Key facts
| NCT number | NCT00362583 |
|---|---|
| Title | Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM) |
| Official title | A Double-blind, Randomised, Placebo-controlled Trial Confirming the Efficacy of Intranasal Fentanyl Titrated to 50, 100 or 200 µg With an Open Long-term Safety Follow-up in Cancer Patients With Breakthrough Pain |
| Lead sponsor | Nycomed, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Fentanyl |
| Enrollment | 100 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Aug 10, 2006 |
| Last update posted | May 7, 2012 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: